Celldex Therapeutics, Inc. (CLDX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CLDX currently has 78.5M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 37.01% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 78.5M shares outstanding |
78M | 0 |
| Apr 02, 2026 |
8-K filing: Celldex Therapeutics, Inc. entered into an underwriting agreement for the offering, issuance, and sale of 10,345,000 shares of common stock at a price of $29.00 per share, with an option for the underwriters to purchase an additional 1,551,750 shares. ($299.91M proceeds) |
66M | 0 |
| Nov 10, 2025 |
10-Q filing | 66.4M shares outstanding |
66M | 0 |
| Aug 07, 2025 |
10-Q filing | 66.4M shares outstanding |
66M | 0 |
| May 08, 2025 |
10-Q filing | 66.4M shares outstanding |
66M | 0 |
| Feb 27, 2025 |
10-K filing | 66.4M shares outstanding |
66M | 0 |
| Nov 06, 2024 |
10-Q filing | 55.9M shares outstanding |
56M | 0 |
| Aug 08, 2024 |
10-Q filing | 55.9M shares outstanding |
56M | 0 |
| May 06, 2024 |
10-Q filing | 65.9M shares outstanding |
66M | 0 |
| Mar 01, 2024 |
8-K filing: Celldex Therapeutics, Inc. entered into an underwriting agreement to offer, issue, and sell 8,520,000 shares of its common stock at a price of $47.00 per share, with net proceeds expected to be approximately $376.2 million; the underwriters have a 30-day option to purchase up to 1,278,000 additional shares. ($376.2M proceeds) |
56M | 0 |
| Feb 26, 2024 |
10-K filing | 55.9M shares outstanding |
56M | 0 |
| Nov 08, 2023 |
8-K filing: Celldex Therapeutics, Inc. entered into an underwriting agreement for the offering, issuance, and sale of 7,425,000 shares of common stock at a price of $27.00 per share, with net proceeds expected to be approximately $188.3 million. ($188.3M proceeds) |
47M | 1.6M |
| Nov 02, 2023 |
10-Q filing | 47.3M shares outstanding |
47M | 1.6M |
| Aug 08, 2023 |
10-Q filing | 47.3M shares outstanding |
47M | 1.6M |
| May 04, 2023 |
10-Q filing | 47.3M shares outstanding |
47M | 1.6M |
| Feb 28, 2023 |
10-K filing | 47.2M shares outstanding |
47M | 1.6M |
| Nov 09, 2022 |
10-Q filing | 46.9M shares outstanding |
47M | 1.9M |
| Aug 08, 2022 |
10-Q filing | 46.8M shares outstanding |
47M | 2.1M |
| May 05, 2022 |
10-Q filing | 46.7M shares outstanding |
47M | 2.1M |
| Feb 28, 2022 |
10-K filing | 46.7M shares outstanding |
47M | 2.1M |
| Nov 09, 2021 |
10-Q filing | 46.7M shares outstanding |
47M | 2.2M |
| Aug 05, 2021 |
10-Q filing | 39.6M shares outstanding |
40M | 9.2M |
| Jul 14, 2021 |
8-K filing: Celldex Therapeutics, Inc. entered into an underwriting agreement for the offering, issuance, and sale of 5,952,381 shares of common stock at $42.00 per share, with net proceeds expected to be approximately $234.8 million. ($234.8M proceeds) |
40M | 9.2M |
| May 06, 2021 |
10-Q filing | 39.6M shares outstanding |
40M | 9.2M |
| Mar 29, 2021 |
10-K filing | 39.6M shares outstanding |
40M | 9.2M |
| Nov 06, 2020 |
8-K filing: Celldex Therapeutics issued 1,554,351 shares of its common stock for aggregate gross proceeds of approximately $12.5 million between June 12, 2020 and November 5, 2020, and filed a prospectus registering the offer and sale of shares of common stock of up to an additional $50.0 million pursuant to the Sales Agreement. ($12.5M proceeds) |
40M | 9.3M |
| Nov 05, 2020 |
10-Q filing | 39.6M shares outstanding |
40M | 9.3M |
| Aug 06, 2020 |
10-Q filing | 39.1M shares outstanding |
39M | 9.7M |
| Jun 17, 2020 |
8-K filing: Celldex Therapeutics, Inc. announced an offering of 13,377,926 shares of common stock at a price of $9.75 per share, with expected net proceeds of approximately $122.7 million; underwriters have an option to purchase up to 2,006,688 additional shares. ($122.7M proceeds) |
23M | 26M |
| Jun 15, 2020 |
8-K filing: Celldex Therapeutics, Inc. sold approximately 6.0 million shares of Common Stock under its Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., with gross proceeds of approximately $24.6 million. ($0.0M proceeds) |
23M | 26M |
| Jun 12, 2020 |
S-3/A filing: Celldex Therapeutics, Inc. is filing an S-3/A to offer common stock, preferred stock, warrants, depositary shares, and units up to a maximum aggregate offering price of $150,000,000. |
18M | 31M |
| Mar 26, 2020 |
10-K filing | 17.6M shares outstanding |
18M | 0 |